Lisa A. Marrero
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>
<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials. </p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children’s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. – Stony Brook University, NY</li>
<li>Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship – The Children’s Hospital of Philadelphia, PA</li>
</ul>
DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.
<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia. </p><p>Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>
<p>Pediatrician, Montefiore Medical Group 2300 Westchester Avenue Bronx, NY 10462 718-829-1900</p>
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal>
<p class="MsoNormal">Karen Warman, MD, MSc, provides general pediatric care for children from infancy through adolescence and teaches medical students and residents.</p><p class="MsoNormal">Dr. Warman is the founder and director of the Pediatric Preventive Asthma Care Program at Montefiore’s Comprehensive Family Care Center. Regionally, she serves on the New York City Asthma Partnership (NYCAP) Steering Committee and co-chairs NYCAP’s Environment Group, which focuses on attaining habitable housing for children with asthma to reduce asthma morbidity. She also serves as a consultant for the American Lung Association-Northeast and the NYC Department of Health. In the latter capacity, she trains school nurses in New York City to manage asthma in the schools.</p><p class="MsoNormal">Dr. Warman has taken a leadership role in several asthma programs. These include: serving as site leader for a Center for Disease Control and Prevention (CDC) sponsored, multi-state replication of the National Cooperative Inner-City Asthma Study (NCICAS); conducting the Physician Asthma Care Education (PACE) training program; and creating, implementing and evaluating the Asthma Passport Program.</p><p class="MsoNormal">Dr. Warman graduated from SUNY Upstate Medical School and completed her residency at Columbia-Presbyterian Medical Center, which is now part of New York-Presbyterian/Columbia University Medical Center.</p>
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>
<p>Bernice M. Vicil, MD, FAAP, is an attending physician and Instructor, Pediatrics at Montefiore Einstein. Dr. Vicil’s clinical focus is in pediatric care.</p><p>After receiving her Bachelor of Arts from Cornell University in 2000, Dr. Vicil completed the Post Baccalaureate Program at State University of New York at Buffalo in 2001. She then pursued her medical education at Einstein, earning her Doctor of Medicine in 2005. In 2008, she completed her pediatric internship and residency at Einstein.</p><p>Dr. Vicil is board certified by the American Board of Pediatrics, and is a Fellow of the American Academy of Pediatrics.</p>
Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>
<p>Allison Taylor, MD, is an Attending Physician at the Children’s Hospital at Montefiore and Assistant Professor of Pediatrics at the Albert Einstein College of Medicine. Her clinical interests focus on General Pediatrics.</p><p>Dr. Taylor received her Bachelor of Arts degree from Brown University and her Doctor of Medicine from the Albert Einstein College of Medicine. She completed her Pediatric residency at Columbia Presbyterian Medical Center and has been working and teaching at the Family Care Center at Montefiore for over 25 years.</p><p>Dr. Taylor is co-director of breastfeeding education for pediatric residents at Montefiore and provides breastfeeding education to expectant mothers through the FCC Child Birth Class series. She is also a strong advocate of early childhood literacy.</p><p>She has been on the Castle Connolly Top Doctors list since 2016. Dr. Taylor is board certified in pediatrics and a fellow of the American Academy of Pediatrics.</p>
Pediatric Medicine
Dr. Tam’s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children.
<p>Ivy Tam, MD, FAAP, is an Attending Physician and a Non-neonatal Emergency Transport Coordinator at Children’s Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. </p><p>In 2009, Dr. Tam received her Bachelor of Arts in Biological Sciences at Cornell University. She then attended SUNY Upstate Medical University, where she received her Doctor of Medicine in 2013. Dr. Tam began her postgraduate training with a residency in pediatrics at New York University School of Medicine, followed by a fellowship in pediatric hospital medicine in 2018 at the University of California San Diego. </p><p>Dr. Tam’s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children. She has shared her work through presentations in academic forums and scientific meetings, and is currently in the process of being submitted for publication. </p><p>2017, Dr. Tam received the CARES Award from hospital staff at Rady Children’s Hospital for her support during the medical director’s absence. Dr. Tam is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics. </p>